November was the smoked-free month, and we hope that it was successful for you!* Indeed, smoking is the first cause of lung cancer, which is the 3th most common cancer and the first leading cause of cancer-related mortality in France, according to The French National Cancer Institute. Worldwide, it is Read more…
ELRIG Drug Discovery 2023 congress will take place in Liverpool next week (October, 18 & 19th 2023). Our project leader Dr. Véronique De Conto will have the pleasure for presenting a poster about High Content Screening in 3D models including the tumoral Extracellular Matrix. Abstract: In oncology, 97% of drug Read more…
Thomas Meynard is a PhD student in OncoLille Laboratory (Canther Lab, Mucine Team), under the supervision of Dr. Isabelle Van Seuningen and Dr. Vincent Senez. His PhD work is focused on the development of microfluidic systems to study Pancreatic Ductal AdenoCarcinoma (PDAC). To reproduce the tumoral Extracellular Matrix (ECM), he Read more…
Rehovot (Israel) London (UK) and Lille (France) Vidac Pharma is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. Vidac Pharma and HCS Pharma announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma Read more…
Metastasis is the leading cause of death in many cancers. Metastases are particularly harmful when they affect vital organs such as the brain or liver, severely compromising the patient’s quality of life and leading to death. The difficulties of studying metastases in animal models (time, cost, ethical issues) have meant Read more…
In recent years, 3D cell culture has emerged as a promising approach to studying the immune system and its interactions with cancer cells. Indeed, 3D cell culture mimics better the natural architecture of tissues and provides a more physiologically relevant models for drug discovery. One of the major advantages of Read more…
A driver oncogene is a gene that, when activated by mutation or altered in expression, contributes importantly to the development and progression of cancer. In other words, alteration of this kind of genes lead to the transformation of a normal cell into a cancerous cell by activating signaling pathways involved Read more…
… And it is right ! “Biomimesys technology can bring several advantages in immuno-oncology by providing a more physiologically relevant 3D cell culture model for research. This technology uses a bioinspired extracellular matrix to create a three-dimensional environment that more closely resembles the natural cellular environment. In immuno-oncology, 2D cell Read more…
Poster presented during the SLAS Building Biology in 3D symposium event in Cambridge on April, 20th 2023. Title: 3D cell culture taking into account the extracellular matrix for bridging the gap between in vitro & in vivo: focus on cancer models V. De Conto 1 *, M. Fernandes2, J. Cicero, Read more…
The event “Research and Innovation 2023 – Accelerating future DD” of The European Laboratory Research and Innovation Group (ELRIG) took place in Cambridge on March 29th and 30th 2023. Our project leader Dr. Veronique De Conto attended this event with our academic partner Dr.Marie Fernandes (CNRS, Oncolille, Canther Lab), who Read more…
HCS Pharma is very pleased to participate to “Building Biology in 3D” symposium of the Society for Laboratory Automation and Screening (SLAS), in Cambridge, United Kingdom 20-21 April 2023. Veronique De Conto, our project leader in in vitro pharmacology will present two digital posters about the use of BIOMIMESYS® hydroscaffold, Read more…
It is with great pleasure that we announce the reinforcement of our collaboration about lung cancer between HCS Pharma and TARGET team of the OncoLille Institute (Team “Efficacy and resistance to anti-tumor targeted therapies”, CANTHER UMR9020, Lille, France). Initially supported by Région Hauts-de-France, this project has been initiated in spring Read more…
It is a pleasure to announce that HCS Pharma has a new collaborative project dealing with Inflammasome et ion channels Team of OncoLille (PHYCELL Lab, INSERM U1003) in the frame of colon cancer, thanks to France Relance plan and Region Hauts-de-France. This project has started in October 2022 for 2 Read more…
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human sciences, etc. Our project leader Véronique De Conto was pleased to present her poster about Read more…
The Extracellular Matrix (ECM) is a major component of all the organs. This dynamic structure is involved not only in cell adhesion, but also in physiological processes, including cell differentiation, migration, and maturation, tissue homeostasis, biochemical signal retention and mediation, and growth factors’ retention. Moreover, the ECM can be abnormally Read more…
Yesterday, the 11th of April, was the World Parkinson’s Day. On this occasion, HCS pharma would like to inform you about this disease and its work for new drug discovery. What is Parkinson’s disease? It is the second most common neurodegenerative disease after Alzheimer’s disease. It is attributed to a Read more…
Increased ExtraCellular Matrix (ECM) stiffness is a common process in many cancers (Pickup et al, 2014). This process influences the behaviour of cancer cells in the tumour microenvironment. The accumulation of ECM in the stroma is mainly due to a high production of ECM molecules by TGF-β(Transforming Growth Factor-beta) -stimulated Read more…
